These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16741003)

  • 1. Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin.
    Maguire JJ; Wiley KE; Kuc RE; Stoneman VE; Bennett MR; Davenport AP
    Exp Biol Med (Maywood); 2006 Jun; 231(6):806-12. PubMed ID: 16741003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
    Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
    Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
    Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V
    Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
    Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
    J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis.
    Nachtigal P; Jamborova G; Pospisilova N; Pospechova K; Solichova D; Zdansky P; Semecky V
    J Pharm Pharm Sci; 2006; 9(2):222-30. PubMed ID: 16959191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study.
    Cristofori PG; Crivellente FA; Faustinelli I; Lanzoni AR; Lazzarini C; Vecchiato E; Andreoli M; Turton JA; Zancanaro C; Crespi FM
    Toxicol Pathol; 2004; 32(4):493-9. PubMed ID: 15223775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
    Bach-Ngohou K; Ouguerram K; Frénais R; Maugère P; Ripolles-Piquer B; Zaïr Y; Krempf M; Bard JM
    J Pharmacol Exp Ther; 2005 Oct; 315(1):363-9. PubMed ID: 16014756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice.
    Miyoshi T; Li Y; Shih DM; Wang X; Laubach VE; Matsumoto AH; Helm GA; Lusis AJ; Shi W
    Life Sci; 2006 Jul; 79(6):525-31. PubMed ID: 16516241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice.
    Massy ZA; Ivanovski O; Nguyen-Khoa T; Angulo J; Szumilak D; Mothu N; Phan O; Daudon M; Lacour B; Drüeke TB; Muntzel MS
    J Am Soc Nephrol; 2005 Jan; 16(1):109-16. PubMed ID: 15563564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5.
    Patel S; Thelander EM; Hernandez M; Montenegro J; Hassing H; Burton C; Mundt S; Hermanowski-Vosatka A; Wright SD; Chao YS; Detmers PA
    Biochem Biophys Res Commun; 2001 Aug; 286(1):164-70. PubMed ID: 11485323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
    Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
    Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice.
    Michel F; Simonet S; Vayssettes-Courchay C; Bertin F; Sansilvestri-Morel P; Bernhardt F; Paysant J; Silvestre JS; Levy BI; Félétou M; Verbeuren TJ
    Am J Physiol Renal Physiol; 2008 Jan; 294(1):F120-9. PubMed ID: 17942572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.
    Raffai RL; Loeb SM; Weisgraber KH
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):436-41. PubMed ID: 15591220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated systemic levels of endothelin-1 and blood pressure correlate with blunted constrictor responses and downregulation of endothelin(A), but not endothelin(B), receptors in an animal model of hypertension.
    Télémaque-Potts S; Kuc RE; Maguire JJ; Ohlstein E; Yanagisawa M; Davenport AP
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():357S-362S. PubMed ID: 12193122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
    Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
    Lee DL; Wamhoff BR; Katwa LC; Reddy HK; Voelker DJ; Dixon JL; Sturek M
    J Pharmacol Exp Ther; 2003 Jul; 306(1):132-40. PubMed ID: 12663685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels.
    Bot I; Jukema JW; Lankhuizen IM; van Berkel TJ; Biessen EA
    Atherosclerosis; 2011 Feb; 214(2):295-300. PubMed ID: 21130458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced atherosclerosis.
    Eto H; Miyata M; Shirasawa T; Akasaki Y; Hamada N; Nagaki A; Orihara K; Biro S; Tei C
    Hypertens Res; 2008 Aug; 31(8):1631-42. PubMed ID: 18971539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.
    Paul A; Ko KW; Li L; Yechoor V; McCrory MA; Szalai AJ; Chan L
    Circulation; 2004 Feb; 109(5):647-55. PubMed ID: 14744975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.